Hepatitis C: Symptoms, Transmission, Treatment & Prevention

Hepatitis C is a bloodborne infection of hepatocytes by hepatitis C virus, a positive-sense RNA virus belonging to the Flaviviridae family. The virus replicates without producing protective neutralising antibodies, so antibody response marks exposure rather than immunity—patterns that contrast with the durable post-vaccine antibody seen after hepatitis A immunisation or natural hepatitis B resolution. Acute injury reflects a mix of cytopathic effect and host immune response; the silent, slow march toward fibrosis explains why most people are diagnosed years after exposure during opportunistic screening.

Seven HCV genotypes and dozens of subtypes are recognised internationally, with genotypes 1a, 1b, 2 and 3 dominating in the United States and a wider mix in lower-income regions. With pan-genotypic direct-acting antivirals now first-line, the bedside relevance of genotype has shrunk: simplified treatment algorithms increasingly skip pretreatment genotyping for non-cirrhotic, treatment-naïve adults, reserving it for prior treatment failures, decompensation or research cohorts.

Around 30% of newly infected adults clear HCV spontaneously, usually within six months, while the rest progress to chronic infection. CDC summarises that approximately 5%–25% of those with chronic HCV develop cirrhosis over 10–20 years, and once cirrhosis is established the annual risk of hepatocellular carcinoma is roughly 1%–4%. Drinking patterns, metabolic comorbidity such as nonalcoholic fatty liver disease, HIV co-infection, male sex and older age at acquisition each accelerate that timeline.

↔On a small screen, swipe or scroll sideways to see the full table.

Most people with acute or chronic HCV look and feel well. When acute symptoms do appear, they are non-specific and overlap any viral hepatitis: fatigue, low-grade fever, nausea, abdominal pain, joint pain and—late in the picture—dark urine with pale stools. Many chronic infections only declare themselves through incidental ALT elevation, opportunistic antenatal screening, blood-donor deferral letters or the development of complications years later.

Patterns that change urgency

• Encephalopathy spectrum: sleep inversion, asterixis or constructional apraxia in a known chronic patient is decompensation until proved otherwise.
• Easy bruising and gingival bleeding alongside thrombocytopenia—evaluate portal hypertension and synthetic function rather than dismissing it as “old age”.
• Itching out of proportion to bilirubin, especially with new joint pain or palpable purpura, can flag HCV-associated cryoglobulinaemic syndromes.

Extra-hepatic manifestations

HCV is more than a liver disease. Established associations include mixed cryoglobulinaemia (sometimes presenting as glomerulonephritis with new proteinuria), porphyria cutanea tarda, lichen planus, type 2 diabetes mellitus through insulin-resistance pathways, and an increased risk of B-cell non-Hodgkin lymphoma. These extra-hepatic syndromes often improve after virological cure—an evidence-based reason to push for treatment beyond preventing cirrhosis.

HCV is essentially a percutaneous virus. In the United States and the UK, sharing equipment for injecting drug use is now the dominant transmission route, eclipsing the historical signal from pre-1992 transfusions and unscreened clotting factor concentrates produced before 1987. Other contemporary routes include reuse or inadequate sterilisation of medical or cosmetic equipment, tattooing and piercing in unregulated settings, perinatal transmission, and sexual practices that involve mucosal blood exposure—particularly among men who have sex with men with HIV.

Healthcare exposure remains a recognisable but smaller hazard: percutaneous injuries with hollow-bore needles from a known HCV-positive source carry a measurable seroconversion risk. Compulsive vigilance with sharps and PPE donning and doffing—particularly during emergencies—drives that risk down.

• Injection drug use with shared needles, cookers or filters—the leading current risk factor.
• Maintenance haemodialysis and persistent ALT abnormalities of unclear origin—test once per CDC guidance.
• Healthcare needlestick or mucosal exposure to HCV-positive blood—occupational health pathway, no PEP medication.
• Pre-1992 transfusion or pre-1987 clotting factors—catch-up screening still finds undiagnosed people.
• Perinatal exposure—test infants per local timing rules; antibody alone before 18 months is unreliable.
• Tattoos or piercings in unregulated facilities; intranasal drug equipment sharing.

Clinical assessment

Take a structured exposure history without judgement: lifetime injection or non-injection drug use, healthcare procedures abroad, occupational sharps history, tattoos/piercings, sexual practices that may bridge blood exposure, and pregnancy plans. Document any extra-hepatic clues—joint pain, palpable purpura, neuropathy, glomerulonephritis—because they widen the differential into HCV-associated immune phenomena.

Laboratory investigations

• Anti-HCV antibody as the screen, with reflex HCV RNA on the same specimen if reactive—aligns CDC, AASLD–IDSA, EASL and WHO guidance.
• Liver function tests with fractionated bilirubin; ALT and AST may be normal even with active replication.
• Quantitative HCV RNA at baseline and at the points required by the chosen DAA pathway (often only at SVR12 in simplified protocols).
• HBsAg and anti-HBc to detect prior or active HBV before DAAs; HIV testing if status unknown.
• Renal panel and pregnancy test as appropriate—some regimens have specific renal or pregnancy considerations and ribavirin is teratogenic.
• Fibrosis staging with non-invasive scores (APRI, FIB-4) and FibroScan; biopsy is reserved for ambiguous cases.

Specialised testing

Genotype and resistance-associated substitution testing are now reserved for prior treatment failures, decompensated cirrhosis, transplant recipients or research cohorts. Abdominal ultrasound images established cirrhosis and the textural features of advanced disease and is the workhorse for HCC surveillance once fibrosis is advanced.

Specimen integrity matters: align specimen collection with laboratory cut-offs (some HCV RNA assays have a lower limit of quantification of about 15 IU/mL) so that very low viraemia is not interpreted as false-negative.

1. Screen — every adult at least once, every pregnancy, anyone with ongoing risk per CDC; document anti-HCV result and trigger reflex RNA on positive specimens.
2. Confirm active infection — quantitative HCV RNA. Negative RNA after positive antibody suggests prior cleared or treated infection; counsel and document, do not treat.
3. Pre-treatment workup — HBsAg, anti-HBc, HIV, renal function, pregnancy test if applicable, fibrosis staging, alcohol and adherence assessment, and a hard look at the medication list for DAA interactions (statins, amiodarone, anticonvulsants, some PPIs, antiretrovirals).
4. Treat — pan-genotypic DAA (commonly sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) for 8–12 weeks; daily oral; few side-effects.
5. Confirm cure — HCV RNA at SVR12 (12 weeks after final dose). Undetectable = cure.
6. Plan post-cure surveillance — ongoing HCC imaging if cirrhotic or advanced fibrosis, harm-reduction support, partner and household testing, alcohol counselling.
7. Escalate — any decompensation, treatment failure, or unexplained ALT rise on DAAs goes to hepatology/ID.

Acute hepatitic chemistry rarely points to one virus alone. Maintain a parallel sweep:

• Hepatitis A and hepatitis B — risk-factor guided serology; coinfection alters management.
• Acute HIV and Epstein–Barr virus — atypical lymphocytosis and risk history may overlap.
• Drug-induced liver injury — review antibiotics, anticonvulsants, herbal stacks and acetaminophen dosing; ingestion timelines matter.
• Autoimmune hepatitis — hypergammaglobulinaemia and autoantibody panels; treatment principles diverge.
• Ischaemic and shock liver — context of hypotension or right-heart failure.
• Biliary obstruction — predominant cholestatic pattern with dilated ducts on imaging.
• Wilson’s disease and haemochromatosis — younger patients with unexplained chronic transaminitis warrant a metabolic sweep.

↔On a small screen, swipe or scroll sideways to see the full table.

Hepatitis C is one of the few chronic viral infections that current oral therapy can reliably cure. AASLD–IDSA, EASL and WHO converge on the same principles: treat virtually everyone with active HCV RNA, choose a pan-genotypic DAA regimen, treat for 8–12 weeks in most simplified pathways, and confirm cure with HCV RNA at SVR12.

First-line DAA options (illustrative)

• Sofosbuvir/velpatasvir — 12-week pan-genotypic regimen, useful in compensated cirrhosis without prior DAA exposure; check renal function and concomitant medication list.
• Glecaprevir/pibrentasvir — typically 8 weeks in treatment-naïve patients without cirrhosis (12 weeks for compensated cirrhosis); preferred where moderate–severe CKD coexists.
• Sofosbuvir/velpatasvir/voxilaprevir — salvage regimen for prior DAA failure under specialist guidance.

Ribavirin is now reserved for selected difficult cases (decompensated cirrhosis, salvage). When it is used, document contraception status and counsel rigorously: ribavirin is teratogenic for both partners.

Drug–drug interactions worth flagging

• Statins — interactions with NS5A and protease inhibitors can raise levels and rhabdomyolysis risk; many regimens require dose reduction or pause.
• Amiodarone with sofosbuvir-based regimens — risk of symptomatic bradycardia; alternatives are usually preferred.
• Anticonvulsants (carbamazepine, phenytoin) and rifampicin reduce DAA exposure and are contra-indicated.
• Proton pump inhibitors can reduce ledipasvir absorption—pharmacy review streamlines admission medication lists.
• Antiretrovirals—ritonavir-boosted protease inhibitors and some integrase combinations interact unpredictably with HCV protease inhibitors. Start with HIV pharmacist review.

Special populations

• Cirrhosis: compensated cirrhosis is treated; decompensated cirrhosis is referred to hepatology because ribavirin-containing or non-protease-inhibitor regimens are usually preferred.
• HIV co-infection: same cure goals; coordinate with the HIV team for interaction screening.
• CKD and dialysis: pan-genotypic DAAs are usable across stages with regimen-specific labelling.
• Pregnancy: universal screening at every pregnancy; routine DAA initiation is not yet standard but emerging evidence supports antenatal treatment in selected cases under specialist supervision.
• Children: WHO and CDC support DAA treatment from age 3 with weight-banded pan-genotypic regimens.

• Adherence anchoring: short DAA courses make missed doses disproportionately costly—use blister packs, daily reminders or directly observed therapy in vulnerable cohorts.
• Follow-up cadence: simplified algorithms often need only a baseline visit, an on-treatment safety check and the SVR12 RNA—escalation criteria should be explicit so non-specialists know when to call hepatology.
• Renal review: check creatinine and eGFR at baseline; renal dosing decisions feed directly into product choice.
• Mental health and substance-use support: integrate harm-reduction and opioid agonist treatment where relevant—DAA cure rates are equivalent in people who inject drugs when wraparound support exists.
• Documentation: note exposure source, baseline RNA, regimen, prescriber, expected SVR12 date and whether cirrhosis status mandates ongoing HCC imaging post-cure.

Infection-prevention bundle

Routine ward care for stable HCV uses standard precautions; HCV is not airborne and does not require a single-room cohort by default. The danger is sharps and blood splash, so reinforce hand hygiene and engineered safety devices. Specific outbreak situations or open wounds may justify isolation precautions per local policy.

• Progressive fibrosis and cirrhosis with portal hypertension, varices, ascites and encephalopathy.
• Hepatocellular carcinoma—even after cure when fibrosis was advanced at the time of SVR12.
• HCV-associated mixed cryoglobulinaemia with cutaneous, renal or neurological involvement.
• Membranoproliferative glomerulonephritis driving CKD progression.
• Type 2 diabetes mellitus, porphyria cutanea tarda, B-cell non-Hodgkin lymphoma.
• HBV reactivation when DAAs are started without HBV serology screening.

There is no licensed HCV vaccine, so prevention is behavioural and structural. WHO and CDC frame the work as five interlocking strands:

• Universal donor blood screening, single-use sharps and safe medical injections.
• Needle and syringe programmes plus opioid agonist therapy as the core harm-reduction package.
• Universal one-time adult screening, screening at every pregnancy, and risk-based repeat testing.
• Treatment as prevention—treating people with chronic HCV reduces onward transmission across networks.
• Workplace safety with engineered devices, immediate exposure reporting and accurate occupational-health serology timing rather than empiric medication PEP (no HCV PEP exists).

Patients with mild fibrosis at SVR12 generally return to age-matched mortality and morbidity expectations; quality of life and many extra-hepatic syndromes improve after cure. Patients with advanced fibrosis or established cirrhosis at the point of cure remain at lifetime risk of HCC and decompensation, although that risk is meaningfully reduced compared with untreated disease. Reinfection is possible at any time when exposure recurs—repeat HCV RNA rather than antibody is the right test if reinfection is suspected.

• “Hepatitis C positive” on a triage card frequently means antibody-positive only—ask for the most recent HCV RNA before deciding isolation, counselling or treatment plans.
• People with a history of alcoholic hepatitis or active alcohol use accelerate HCV fibrosis—integrate alcohol-reduction support rather than refusing DAAs.
• Stigma is the silent barrier to cure. Confidential, non-judgemental language about injection drug use, sexual practices and incarceration history elicits accurate exposure data.
• Take time over discharge counselling: the expected SVR12 date, what to do if doses are missed and how reinfection risk applies after cure are easy to skip and expensive to undo.

• Vitals: document baseline and any deterioration with vital signs measurement; trend NEWS2 or local equivalent.
• Neuro: sleep–wake reversal, attention, asterixis—daily in known cirrhosis.
• Hemostasis: mucosal bleeding, bruising trend; baseline INR plus repeat per protocol.
• Hepatic synthetic: bilirubin, albumin, glucose; rising bilirubin while transaminases settle is a warning, not reassurance.
• Adherence: count remaining DAA tablets at every contact; explore practical barriers before assuming non-engagement.
• Drug reconciliation: formal medication reconciliation before starting DAAs and at every change.
• Sharps/IPC: safe device handling at every IV insertion and dressing change.

Red-flag symptom clusters

• Worsening sleep inversion, asterixis or new disorientation.
• New ascites or rapidly enlarging girth with abdominal pain or fever.
• Mucosal bleeding, petechiae or rapidly falling platelets.
• Diuresis-resistant peripheral oedema with rising creatinine.

Objective findings

• INR >1.5 with or without overt bleeding.
• Serum bilirubin trending up while transaminases plateau or fall.
• Capillary glucose <3.5 mmol/L (≈63 mg/dL) without dietary explanation.
• Imaging features of new HCC, portal vein thrombosis or significant portal hypertension.

Escalation mechanics

• Ward: immediate registrar review for any new encephalopathy grade ≥1, INR rise above local threshold, or active bleeding.
• Hepatology / transplant unit: when synthetic decompensation persists, candidacy for transplant or ascites management changes.
• Critical care: early referral when vasopressor need is anticipated, large-volume bleeding develops or grade 3–4 encephalopathy emerges.

Pre-treatment

• Capture exposure, alcohol, mental health and pregnancy status; document medication list and supplements honestly to drive interaction screening.
• Confirm baseline labs are filed (anti-HCV with quantitative HCV RNA, HBV serology, HIV, eGFR, LFTs, fibrosis stage).
• Reinforce harm-reduction conversations and safety-net escalation triggers in plain language.

During DAA therapy

• Reinforce daily dosing; troubleshoot side-effects (mostly mild headache, fatigue or insomnia) before patients self-discontinue.
• Coordinate clinic appointments around opioid agonist therapy or shelter timetables for vulnerable cohorts.
• Document any unscheduled use of acetaminophen, herbal supplements or recreational substances that may affect DAAs.

Post-treatment / SVR12

• Confirm HCV RNA at 12 weeks after the last dose; communicate cure clearly and document SVR12 in the chart and discharge letter.
• Schedule HCC surveillance ultrasound for cirrhotic or advanced-fibrosis patients—this is the easiest follow-up to lose.
• Plan partner and household testing, and align reinfection messaging with ongoing risk; offer hepatitis A and B vaccination if susceptible.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a cloze drop-down on the topic of reflex HCV RNA testing, the pan-genotypic DAA cure pathway, SVR12 confirmation and decompensation red flags—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.